drugset
drugset / Trial / NCT05918224

Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy

NCT05918224 ↗

Phase 2 Completed 160 enrolled West China Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate the efficacy and safety of Streptococcus salivarius K12 for prevention and treatment of oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors.

Timeline

Start
2022-01-01
Primary completion
2022-11-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Streptococcus salivarius K12 Unknown — Oral

Indications

head and neck squamous cell carcinoma